Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Eurand files NDA for Zentase for the treatment of exocrine pancreatic insufficiency

Eurand has announced that Eurand Pharmaceuticals Ltd. initiated the rolling submission of its new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for Zentase for the treatment of Exocrine Pancreatic Insufficiency (EPI). Zentase (formerly EUR-1008), the company's lead product candidate, has been granted fast-track designation by the FDA.

14 Jun 2007

Underuse of pancreatectomy in the United States

More than half of eligible patients with operable, early-stage pancreatic cancer don't undergo potentially life-extending surgery, suggests a study published online in the Annals of Surgery, published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

8 Jun 2007

Dietary vitamin B6. B12 and folate, may decrease pancreatic cancer risk among lean people

Researchers exploring the notion that certain nutrients might protect against pancreatic cancer found that lean individuals who got most of these nutrients from food were protected against developing cancer.

3 Jun 2007

Common cancer gene p53 sends death order to tiny killer

Scientists at Johns Hopkins have discovered one way the p53 gene does what it's known for stopping the colon cancer cells.

1 Jun 2007

Swedish 'snus' linked to a doubled risk of pancreatic cancer

People who use Swedish moist snuff (snus) run twice the risk of developing cancer of the pancreas.

11 May 2007

Scientists discover way to distinguish pancreatic cancer from non-cancerous tissue

The research examined pancreatic cancer cells for tiny molecules called microRNA (miRNA). It shows that relative levels of certain miRNAs can distinguish pancreatic cancer from nearby noncancerous tissue and from inflamed pancreatic tissue.

2 May 2007

Expression pattern of microRNA may be useful in differentiating between chronic pancreatitis and pancreatic cancer

Pancreatic cancer is a lethal disease, with the annual deaths nearly equaling the incidence of 33,000 in the United States, according to background information in the article.

2 May 2007

Biomarker discovery bodes well for better cancer diagnostics

While new findings from Ohio State University scientists suggest a genetic marker that could help distinguish between chronic pancreatitis and pancreatic cancer and gauge who will do well with cancer treatment, a pharmacologist at the Kimmel Cancer Center at Jefferson in Philadelphia sees the discovery as much more.

2 May 2007

Anti-reflux valve improves quality of life for cancer patients

An anti-reflux valve developed to help esophageal cancer patients also has been shown to help those with bile duct obstruction, according to Kulwinder S. Dua, M.D., a research physician at the Medical College of Wisconsin in Milwaukee.

30 Apr 2007

Tarceva extends life of patients with pancreatic cancer

New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine chemotherapy significantly improves survival by 22 percent in patients with advanced pancreatic cancer.

27 Apr 2007

Anti-reflux biliary stent helps those with bile duct obstruction

26 Apr 2007

Aspirin use linked to moderate drop in cancer risk

A new American Cancer Society study finds men and women who used adult-strength aspirin (325 mg or more) daily for five or more years had an approximately 15 percent lower rate of developing any cancer than those who did not use aspirin.

20 Apr 2007

Triphala hinders the growth of pancreatic cancer cells

A new study from the University of Pittsburgh Cancer Institute suggests that a commonly used herbal supplement, triphala, has cancer-fighting properties that prevent or slow the growth of pancreatic cancer tumors implanted in mice.

18 Apr 2007

Vaccine halts progression of pancreatic cancer in some patients

A dendritic cell-based therapeutic vaccine for pancreatic cancer developed by researchers at the University of Pittsburgh School of Medicine has successfully stalled the disease from progressing in a handful of patients three years post-vaccination.

18 Apr 2007

Aspirin may modestly reduce cancer risk

A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.

18 Apr 2007

Early stage pancreatic cancer expresses antigen targeted by Immunomedics' PAM4 antibody

Immunomedics has reported in an oral presentation at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) that the antigen targeted by the humanized PAM4 antibody is expressed in early stage pancreatic cancer specimens, a stage before the tumor becomes invasive.

18 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

Taking a jab at cancer by stimulating the immune system

As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress.

18 Apr 2007

Johns Hopkins develops pancreas cancer risk software tool

People with a family history of pancreas cancer now have a way to accurately predict their chance of carrying a gene for hereditary pancreas cancer and their lifetime risk of developing the disease.

17 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007